Connect with us

Markets & Industry

Patent application filed for ketamine as behavioural addiction treatment

Published

on

Patent application filed for ketamine as behavioural addiction treatment

Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy. 

The successful completion of Awakn’s behavioural addictions study was announced last week and the data provided from the study was used in the patent filing. 

The pilot study investigated ketamine as a potential new treatment approach for Gambling Disorder, Internet Gaming Disorder, Compulsive Sexual Behavior Disorder and Binge Eating Disorder.

The PCT covers all behavioural addictions or any recognised disorder or condition with similar compulsive symptoms to those in the study. If granted, the patent claims would give Awakn exclusive rights to use ketamine and ketamine-assisted therapy for the treatment of behavioural addictions.

Awakn CEO, Anthony Tennyson, commented: “Today’s news demonstrates our focus on researching, developing and commercialising therapeutics to treat addiction.  

“A core part of our efforts is to continually strengthen our IP portfolio as we work to bring effective therapies to chronic addiction sufferers in desperate need. 

“To be forging a path to find an effective treatment for such a vast unmet medical need is critical and an effort we are very proud to be a part of.”

With no effective pharmacological treatments available globally at present for behavioural addictions, the study results and the patent filing position Awakn at the forefront of the industry at a time when rates of behavioural addictions are increasing at an alarming pace and sufferers have few treatment options which deliver poor outcomes.

The promising results from the pilot study showed a reduction of symptoms for some participants, with some participants no longer meeting the criteria for a diagnosis. Some individuals also showed a reduction of the symptoms of a comorbid psychiatric condition, such as depression or anxiety. The treatment was also well tolerated with no safety concerns.

See also  Proprietary DMT molecule shows positive preclinical data

Gambling Disorder, Internet Gaming Disorder, and Binge Eating Order are all recognised in the DSM-5, which is a diagnostic tool that serves as the principal authority for psychiatric diagnoses in the US, and affect up to 450 million, 235 million and 100 million people respectively. While Compulsive Sexual Behavior Disorder, which is included in the ICD-11, affects up to 350 million[4] people. 

The ICD-11 was developed by the World Health Organization (WHO) and is the global standard for recording health information and causes of death. Current standard of care for all of these conditions is poor.

Markets & Industry

Small Pharma receives patent grant for DMT injectable formulation

The patent will also protect novel injectable formulations of other known psychedelic compounds.

Published

on

Small Pharma receives patent grant for DMT injectable formulation

UK-based Small Pharma has announced that its DMT patent strategy has been strengthened with a new US patent protection on injectable DMT delivery in its lead programmes SPL026 and SPL028.

Small Pharma has received Issue Notification from the United States Patent and Trademark Office that its patent application will be granted on 9 August, 2022 in the US.

The patent is for novel injectable formulations of N, N-dimethyltryptamine (“DMT”) based compounds, and includes novel injectable formulations of other psychedelic compounds, including 5-MeO-DMT and psilocybin.

See also  World’s first DMT-assisted therapy trial successfully completes first phase

Chief Innovation and Intellectual Property Officer of Small Pharma, Peter Rands, said: “Our focus is on developing novel and scalable mental health treatments for patients who are under-served by current medicines. 

“This means diligent assessment of both clinical and commercial potential, and requires a strong patent approach to protect our formulations. We believe that this patent, covering our two most advanced DMT programmes, SPL026 and SPL028, will provide protection of those assets until August 2041. 

“We have focused on protecting our pipeline assets through novel chemistry and, in this case, optimized finished dosage forms.”

The patent represents Small Pharma’s ninth issued patent, and will be the first US patent grant within the company’s psychedelic portfolio, which includes over 70 pending applications, and includes formulations of DMT, the active ingredient in SPL026, and of deuterium-substituted DMT, including the active ingredient in SPL028. 

George Tziras, Chief Executive Officer, added: “This US patent represents a major milestone in our development strategy. It is also timely, as we anticipate dosing completion in our SPL026 Phase IIa trial in patients with Major Depressive Disorder, and prepare for a Phase I study of SPL028 in healthy volunteers in the second half of this year. 

“For Small Pharma’s longer-term vision, the  U.S. will be an important market for DMT-assisted therapies as we look to shape the future of mental health treatments.”

Continue Reading

Markets & Industry

Psychedelic therapeutics market projected to hit $8.31bn by 2028

A new report suggests the market will grow at CAGR of 13.2 per cent from 2022 to 2028.

Published

on

Psychedelic therapeutics market projected to hit $8.31bn by 2028

InsightAce Analytic has projected that the global psychedelic therapeutics market, valued at US$3.61bn in 2021, is expected to reach US$8.31bn (~£6.92bn) by 2028.

With a growing number of people across the globe experiencing poor mental health, not all of which respond to traditional treatments, there is an increasing need for innovative therapies. A growing body of research is now demonstrating that psychedelics could hold promise as treatments for a number of mental health indications.

The new report from InsightAce Analytic suggests that this rise in poor mental health, compounded by the Covid-19 pandemic, along with changed lifestyles and quality of living are fuelling the growth of the psychedelic medicine market.

See also  Advancing psychedelic therapy across Europe

It also highlights that increasing research and development initiatives and the introduction of breakthrough medications that have exhibited efficiency in patients with severe psychological disorders are expected to generate considerable opportunities in the market. 

In 2021, North America dominated the market, and is anticipated to retain its dominance through to 2028 due to the increasing incidence of depression and mental disorders, improved mental health awareness and a rise in research and development efforts. In addition, the increase in mental health-related activity in the healthcare industry to create innovative therapies bolstered regional growth.

As well as including key players in the market, the report explores significant developments that have spurred its growth.

It highlights that, in March 2022, COMPASS Pathways plc entered into a long-term strategic agreement to establish The Centre for Mental Health Research and Innovation to boost psychedelic research and create new mental health treatment modes in the UK. The partnership will speed research into developing psychedelic treatments, promote therapist training and certification, analyse real-world evidence and prototype digital tools to facilitate personalised, predictive and preventative care models.

Other key developments include Mind Medicine announcing the initiation of Project Angie in 2021. The project is aiming to promote the research and development of psychedelics, including LSD, as pain treatments.

Despite positive progression for the market, however, the report also highlights that the wider acceptance of non-therapeutics therapies over allopathic therapies, along with stringent regulations imposed by various governments to commercialise psychedelic medicines, may restrain the market’s growth.

To read the full report please click here.

Continue Reading

Markets & Industry

Provisional patent filed for psilocybin-based compound

The compound has been designed to treat mental health disorders. 

Published

on

Provisional patent filed for psilocybin-based compound

PsiloTec Health Solutions Inc., operating as Zylorion Health, has filed its third provisional patent application with the United States Patent and Trademark Office (USPTO).

Zylorion Health is focused on precision mental health care and psychedelic therapy. The provisional patent application covers the composition of matter of Zylorion’s novel psilocybin-based compound, ZYL-314.

The compound will be used for the treatment of mental health disorders and other central nervous system conditions and cognitive disorders.

See also  Brain activity in depressed people increases following psilocybin use

CEO, Dr Peter Silverstone, commented: “Our clinical team has been working tirelessly with our research partners on the development of novel second generation and industry leading compounds, and we are extremely excited about this discovery.

“ZYL-314 is truly unique and achieving this milestone demonstrates Zylorion’s commitment to bringing innovative new therapies to market and creating long-term shareholder value through a strong portfolio of intellectual property assets.”

The company continues to gather the necessary data and evidence to support the claims and conversion of the composition of matter provisional patent and anticipates filing an application under the PCT (Patent Cooperation Treaty) within the next twelve months.

Zylorion is currently engaged in the development and delivery of integrated precision mental health therapies to address psychological and neurological mental health conditions. 

It is focussing on the research, development and commercialisation of psychedelic-based compounds coupled with novel therapeutic treatment programmes targeting a continuum of mental health conditions, such as major depressive disorder, treatment resistant depression, post-traumatic stress disorder, general depression, anxiety disorders, and a number of addictive tendencies. 

Zylorion has stated that it aims to leverage leading technologies to support the scalability and accessibility of its integrated therapy programmes in its mission to enable those experiencing mental health challenges to thrive.

Continue Reading

Trending

Psychedelic Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. We do not provide medical advice or promote the personal use of psychedelic compounds. Please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.